# GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

> **NCT00122005** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Providence Health & Services** · enrollment: 18 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** GM-CSF gene transduced allogeneic vaccine GVAX

## Key facts

- **NCT ID:** NCT00122005
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2009-02-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122005, "GVAX in Advanced Prostate Cancer Patients Made Lymphopenic". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00122005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*